BACKGROUND: Decay-accelerating factor (DAF) is one of the key molecules involved in cell protection against autologous complement, which restricts the action of complement at critical stages of the cascade reaction. The effect of DAF on the survival of human cervical cancer cell (ME180) has not been demonstrated. METHODS: In this study we applied, for the first time, small interference RNA (siRNA) to knock down the expression of the DAF with the aim of exploiting complement more effectively for tumor cell damage. Meanwhile, we investigated the effects of DAF on the viability and migration, moreover the proliferation of ME180 cell. RESULTS: The results showed that the expression of DAF was significantly increased in human cervical cancer tissues. SiRNA inhibition of DAF expression enhanced complement-dependent cytolysis up to 32% in ME180 cells, which contributed to the control of C3 activation and increased the cells viability, migration and augment the number of ME180 cells. CONCLUSION: These data indicated that DAF siRNA described in this study may offer an additional alternative to improve the efficacy of antibody- and complement-based cancer immunotherapy.
BACKGROUND:Decay-accelerating factor (DAF) is one of the key molecules involved in cell protection against autologous complement, which restricts the action of complement at critical stages of the cascade reaction. The effect of DAF on the survival of human cervical cancer cell (ME180) has not been demonstrated. METHODS: In this study we applied, for the first time, small interference RNA (siRNA) to knock down the expression of the DAF with the aim of exploiting complement more effectively for tumor cell damage. Meanwhile, we investigated the effects of DAF on the viability and migration, moreover the proliferation of ME180 cell. RESULTS: The results showed that the expression of DAF was significantly increased in human cervical cancer tissues. SiRNA inhibition of DAF expression enhanced complement-dependent cytolysis up to 32% in ME180 cells, which contributed to the control of C3 activation and increased the cells viability, migration and augment the number of ME180 cells. CONCLUSION: These data indicated that DAF siRNA described in this study may offer an additional alternative to improve the efficacy of antibody- and complement-based cancer immunotherapy.
Authors: Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch Journal: J Natl Cancer Inst Date: 2006-03-01 Impact factor: 13.506
Authors: Johan van Beek; Marjan van Meurs; Bert A 't Hart; Herbert P M Brok; Jim W Neal; Alexandra Chatagner; Claire L Harris; Nader Omidvar; B Paul Morgan; Jon D Laman; Philippe Gasque Journal: J Immunol Date: 2005-02-15 Impact factor: 5.422
Authors: Yvonne Richaud-Patin; Beatriz Pérez-Romano; Eduardo Carrillo-Maravilla; Alma B Rodriguez; Abraham J Simon; Javier Cabiedes; Juan Jakez-Ocampo; Luis Llorente; Alejandro Ruiz-Argüelles Journal: Immunol Lett Date: 2003-08-05 Impact factor: 3.685
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702